New York, NY -- (SBWIRE) -- 01/23/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Document Security Systems, Inc (NYSEMKT:DSS), Infinera Corp (NASDAQ:INFN), Arca Biopharma Inc (NASDAQ:ABIO), Rentech, Inc (NASDAQ:RTK)
Document Security Systems, Inc (NYSEMKT:DSS) showed a volume of 1.97 million shares by the end of last trade whereas the average volume of the stock remained 1.14 million shares. The stock opened the session at $1.37 but then moved to $1.48. At that price, the stock showed a positive performance of 8.03%. Document Security Systems, Inc. (DSS) develops, markets, secure technologies. The Company specializes in fraud and counterfeit protection for all forms of printed documents and digital information. The Company holds numerous patents for optical deterrent technologies that provide protection of printed information from unauthorized scanning and copying.
Will DSS Continue To Move Higher? Find Out Here
Infinera Corp (NASDAQ:INFN) opened the session at $7.54 and closed the session at $7.62. The stock showed a positive performance of 0.79% in previous trading session. Traded with volume of 1.95 million shares in the prior session and the average volume of the stock remained 1.74 million shares. Infinera Corporation (Infinera) provides optical networking equipment, software and services to communications service providers, Internet content providers, cable operators and subsea network operators (collectively, Service Providers) across the globe.
For How Long INFN will fight for Profitability? Read This Trend Analysis report
Arca Biopharma Inc (NASDAQ:ABIO) opened the session at $2.12 and closed the session at $2.16. The stock showed a positive performance of 1.89% in previous trading session. Traded with volume of 1.95 million shares in the prior session and the average volume of the stock remained 1.46 million shares. The beta of the stock remained 2.49. ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company's principal focus is developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA's lead product candidate is Gencaro TM (bucindolol hydrochloride),
Why Should Investors Buy ABIO After The Recent Gain? Just Go Here and Find Out
Rentech, Inc (NASDAQ:RTK) the stock advanced 2.00% and finished the session at $2.04. Traded with volume of 1.91 million shares in the prior session and the average volume of the stock remained 2.31 million shares. The beta of the stock remained 2.40. Rentech, Inc. (Rentech) is a provider of clean energy solutions. The Company owns and operates a nitrogen fertilizer plant in East Dubuque, Illinois, that manufactures and sells natural gas-based nitrogen fertilizer products within the corn-belt region in the United States.
Will RTK Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)